EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting

Millie D Long, Anita Afzali, Monika Fischer, David Hudesman, Maisa Abdalla, Robert McCabe, Benjamin L Cohen, Ryan C Ungaro, Will Harlan, John Hanson, Gauree Konijeti, Steven Polyak und 7 weitere

Inflammatory Bowel Diseases · 2023

DOI: 10.1093/ibd/izac121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Millie D Long und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Colitis, Biological Products. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Using a novel electronic reporting tool, we aimed to prospectively describe the onset of tofacitinib efficacy during induction therapy in a real-world study.

Methods

Patient-reported outcome data (PROs) including the simple clinical colitis activity index (SCCAI), PRO Measurement Identification Systems (PROMIS) measures, and adverse events were collected daily for the first 14 days and at day 28 and 56. Paired t tests and P for trend were utilized to compare changes in SCCAI over time. Bivariate analyses and logistic regression models were performed to describe response (SCCAI <5) and remission (SCCAI ≤2) by clinical factors.

Results

Of all included patients (n = 96), 67% had failed ≥2 biologics, and 61.5% were on concomitant steroids. Starting at day 3, PROs showed significant and persistent decline of the mean SCCAI (−1.1, P < 000.1) including significantly lower SCCAI subscores for stool frequency (−0.3; P < .003), bleeding (−0.3; P < .0002) and urgency (−0.2; P < .001). Steroid-free remission at day 14, 28, and 56 was achieved in 25%, 30.2%, and 29.2% of patients, respectively. Neither prior biologics nor endoscopic severity were independently predictive of response or remission in multivariate models. Numeric improvements in all PROMIS measures (anxiety, depression, social satisfaction) were seen through day 56. Rates of discontinuation due to adverse events were low.

Conclusions

In this prospective real-world study, tofacitinib resulted in a rapid and persistent improvement in UC disease activity PROs. The safety findings were consistent with the established safety profile of tofacitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeColitisBiological ProductsHumansProspective StudiesBiological FactorsPiperidinesPyrimidines

Stichwörter der Autor:innen

patient report outcomessafetytofacitinibulcerative colitis

Substanzen

Biological FactorsBiological ProductstofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, NC, USA.
  • Ohio State University, Division of Gastroenterology and Hepatology, Columbus, OH, USA.
  • Indiana University, Division of Gastroenterology and Hepatology, Indianapolis, IN, USA.
  • NYU Langone Medical Center, New York, NY, USA.
  • University of Rochester, Division of Gastroenterology and Hepatology, Rochester, NY, USA.
  • MNGI Digestive Health, Minneapolis, MN, USA.

ORCID-Profile: Hans H Herfarth

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Long, M. D., Afzali, A., Fischer, M., Hudesman, D., Abdalla, M., McCabe, R., Cohen, B. L., Ungaro, R. C., Harlan, W., Hanson, J., Konijeti, G., Polyak, S., Ritter, T., Salzberg, B., Seminerio, J., English, E., Zhang, X., Sharma, P. P., & Herfarth, H. H. (2023). Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac121

Vancouver

Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, et al. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac121

BibTeX
@article{Long2023,
  author = {Long, Millie D and Afzali, Anita and Fischer, Monika and Hudesman, David and Abdalla, Maisa and McCabe, Robert and Cohen, Benjamin L and Ungaro, Ryan C and Harlan, Will and Hanson, John and Konijeti, Gauree and Polyak, Steven and Ritter, Timothy and Salzberg, Bruce and Seminerio, Jennifer and English, Emily and Zhang, Xian and Sharma, Puza P and Herfarth, Hans H},
  title = {Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  doi = {10.1093/ibd/izac121}
}
Kostenlos starten →